Skip to content
Tuesday, November 17, 2026 · Today’s edition, 6:30 a.m. ETTue, Nov 17 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in

SPMDvsXPH

SPDR Portfolio S&P 400 Mid Cap ETF against SPDR S&P Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
SPMD 115XPH 127Nov 25Nov 26GROWTH OF $100
Head to head
SPMDXPH
Expense ratio0.030%0.35%
Assets$18.8B$528M
Net flow, 1 month+$250M+$50M
Net flow, 1 year+$2.5B+$263M
Return, YTD+9.9%+16.7%
Return, 1 year——
Avg daily volume2.6M208K
Holdings40061
ListedNov 8, 2005Jun 19, 2006
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

ETF Dailyfrom Private Wealth Daily

ETF launches, fund research, and market coverage in your inbox every morning. Free.

Free. Every morning. Unsubscribe from any edition in one click.